Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369727 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design
A Phase 1 study, sponsored by Moberg Pharma AB.
- Completed
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT06369727: Completed Phase 1 study, sponsored by Moberg Pharma AB.
NCT06369727 is a Phase 1 study that has completed, run by Moberg Pharma AB. The registered enrollment target is 250 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06369727, a Phase 1 study, has completed, sponsored by Moberg Pharma AB.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential
Primary Outcome
Evaluation of dermal reactions at the application sites assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation.
Interventions
- DRUG MOB015B
- DRUG MOB015B vehicle
- DRUG Negative irritant solution of 0.9% saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2017-10-15 |
| Est. Completion | 2018-02-15 |
| Phase | Phase 1 |
What the finished NCT06369727 record still lists
NCT06369727 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher).
The record links to 0 conditions, and to 3 interventions - of which MOB015B is the first listed.
NCT06369727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06369727 about?
NCT06369727 is a clinical study titled "Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design". A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential
What is the current status of trial NCT06369727?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2017-10-15. Estimated completion is 2018-02-15.
What interventions are being tested in trial NCT06369727?
The interventions under investigation include: MOB015B (DRUG), MOB015B vehicle (DRUG), Negative irritant solution of 0.9% saline (DRUG).
Who is sponsoring clinical trial NCT06369727?
This trial is sponsored by Moberg Pharma AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06369727's enrollment target sits among peer trials
250 173rd of 2000 higher than 1,816 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI